DPP4 inhibitors, such as sitagliptin and gemigliptin, have shown potential in ameliorating hepatic steatosis and inflammation in MASLD by modulating glucose metabolism and inflammatory pathways [27]. The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatotic liver disease.